-+ 0.00%
-+ 0.00%
-+ 0.00%

Stocks in play: BioVaxys Technology Corp

Barchart·12/17/2025 08:58:00
Listen to the news

Announces positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S") along with neoadjuvant hormone therapy in women with hormone receptor positive HER2 negative (HR+HER2-) stage II-III breast cancer. BioVaxys Technology Corp shares C.BIOV are trading up $0.02 at $0.24.

Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=7298889010506122